3i Group plc - Q3 performance update

3i Group PLC
30 January 2025
 

 

 

 

 

A good compounding quarter for 3i

·      Increase in NAV per share to 2,457 pence (30 September 2024: 2,261 pence) and total return of 20% for the nine months to 31 December 2024, after a negative foreign exchange translation impact of £476 million, or 49 pence.

 

·      Action produced another outstanding result with very strong sales, EBITDA and cash generation in 2024. In the 12 months to 29 December 2024, net sales and operating EBITDA were 22% and 29% ahead of 2023.

·      Action's like-for-like ("LFL") sales growth was 10.3% in the year (2023: 16.7%) and 352 net new stores were added compared to 303 in 2023.

·      3i received a dividend from Action of £215 million in December 2024. After this distribution, Action ended 2024 with a cash balance of €814 million. Action also completed an amend and extend transaction on approximately 40% of its senior debt in November 2024, resulting in a significant interest cost saving and extended debt maturities.

·     The majority of our remaining Private Equity portfolio companies are performing resiliently, despite a difficult macroeconomic environment. We continued to see strong contributions from a number of our consumer and private label portfolio companies. A small number of assets exposed to discretionary consumer spending and the recruitment market continue to experience challenging conditions.

 

·     We signed a £121 million new investment in WaterWipes in December 2024, which completed in January 2025, and completed four bolt-on acquisitions across our existing Private Equity portfolio. We also completed the realisation of WP in October 2024, which returned proceeds of £280 million to 3i, at an 18% premium over 31 March 2024 value. In January 2025, we signed a new investment in OMS Prüfservice, with completion expected in Q4 FY2025.

 

·     We enter the final quarter of our financial year with a well-funded balance sheet. At the end of December 2024, the Group had gross cash of £792 million, an undrawn RCF of £900 million and gearing was 2%.

 


Last 12 months to P12 2024

Last 12 months to P12 2023


(29 December 2024)

(31 December 2023)

Financial metrics

€m

€m

Net sales

13,782

11,324

LFL sales growth

            10.3%

            16.7%

Operating EBITDA

2,076

1,615

Operating EBITDA margin

            15.1%

            14.3%

Run-rate EBITDA

2,251

1,753

Net new stores added

352

303

Portfolio company

Type

Business description

Date

£m

Royal Sanders

Further

Private label and contract manufacturing producer of personal care products

Oct 2024

39

ten23 health

Further

Biologics focused CDMO

Various

15

Other

Further

Various

Various

4

Total Q3 cash investment

58

Total investment in H1 FY2025

888

Total cash investment as at 31 December 2024

946

In December 2024, we signed the acquisition of WaterWipes, a global, premium, natural wet wipe brand focused on the baby category, with new product innovation in the adult category. This transaction completed on 22 January 2025 with 3i investing £121 million. In January 2025, we also signed a new investment in OMS Prüfservice, the largest specialised service provider in testing electrical systems and equipment for B2B customers in the DACH region,
with completion expected in Q4 FY2025.

In the period, we completed four bolt-on investments, all of which were self-funded by our portfolio companies. Constellation completed its first bolt-on acquisition under our ownership, with the addition of ILKI, a cloud architecture specialist based in France, and Evernex acquired Ultra Support, a leading UK-based third-party maintenance provider, adding local in-house technical and delivery capabilities, as well as a granular geographic coverage of the UK. MAIT acquired TFH technical services, a Dutch consulting provider specialising in the implementation and use of product lifecycle management software solutions and AES added PSS Marine Seal to its core business.

 

Portfolio company

Type

Date

£m

WP

Full Realisation

Oct 2024

277

Other

Various

Various

1

Total Q3 FY2025 realised proceeds

 

278

Total realised proceeds in H1 FY2025

 

1,548

Total realised proceeds as at 31 December 2024

 

1,826

 

 

 

Valuation

Valuation

 

Activity in the quarter

Valuation

Valuation

Sep-24

Dec-24

basis

currency

£m

£m

Action

Earnings

EUR

15,543

17,139

£215 million dividend proceeds received

3iN

Quoted

GBP

918

853

£17 million dividend recognised

Royal Sanders

Earnings

EUR

695

783

£39 million further investment

Cirtec Medical

Earnings

USD

583

628

 

Scandlines

DCF

EUR

519

520

£7 million dividend received

AES Engineering

Earnings

GBP

407

406

£4 million dividend received. Self-funded acquisition of PSS Marine Seal in October 2024

Tato

Earnings

GBP

372

377

£8 million dividend received

SaniSure

Earnings

USD

312

334

 

Evernex

Earnings

EUR

329

329

Self-funded acquisition of Ultra Support in November 2024

Smarte Carte

DCF

USD

283

312

 

1. The valuations are translated at the spot rate of the balance sheet date. Sterling weakened by 6.6% against the US dollar and strengthened by 0.6% against the euro in the quarter to 31 December 2024. Individual valuations exclude the benefit of the foreign exchange hedges.


1.

Balance sheet values are stated net of foreign exchange translation. Where applicable, the GBP equivalents at 31 December 2024 in this update have been calculated at a currency exchange rate of €1.2097: £1 and $1.2527: £1 respectively.

2.

At 31 December 2024 3i had 968 million diluted shares. 

3.

Action was valued using a post-discount run-rate EBITDA multiple of 18.5x based on its LTM run-rate earnings to 29 December 2024 of €2,251 million.

4.

As at 31 December 2024, the notional amount of the forward foreign exchange contracts held by the Group was €2.6 billion (including €600 million associated with Scandlines) and $1.2 billion.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

3i Group (III)
UK 100

Latest directors dealings